Corbus Barclay 4
4 · BED BATH & BEYOND, INC. · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
BBBY Director Corbus Barclay Receives Award, Converts RSUs
What Happened Corbus Barclay, a director of Bed Bath & Beyond, had restricted stock units (RSUs) vest and convert into 26,873 shares on May 15, 2026; those 26,873 shares were reported as both acquired (conversion) and disposed on the same date. Separately, Barclay was granted 35,181 RSUs on May 14, 2026 (these RSUs carry a $0.00 grant price and vest later). The filing also shows 7,816 warrants issued October 7, 2025 (warrant exercise price $15.50).
Key Details
- Transaction dates: RSU grant 5/14/2026 (35,181 RSUs, $0.00 grant price); RSU vest/convert and same‑day disposition 5/15/2026 (26,873 shares; acquisition reported N/A and disposition reported $0.00); earlier pro‑rata warrant distribution 10/07/2025 (7,816 warrants).
- Prices/values: RSU grants reported at $0.00 (typical for restricted awards). Warrants carry a $15.50 exercise price per warrant. The disposed shares are reported with $0.00 value in the filing (reported as a derivative transaction).
- Shares/units remaining after transactions (per filing): 35,181 restricted stock units from the 5/14/2026 grant (vesting 5/14/2027) and 7,816 warrants from the 10/07/2025 distribution. The 26,873 RSUs that vested on 5/15/2026 were converted and reported as disposed on the same date.
- Footnotes: F1 notes the 26,873 RSUs vested at close of business on 5/15/2026 and vested shares are delivered promptly after vesting. F2 notes the 35,181 RSUs vest on 5/14/2027. F3 explains the 7,816 instruments are warrants from a 10/07/2025 pro‑rata distribution (exempt from immediate reporting) exercisable at $15.50 each.
- Filing timeliness: Form 4 was filed 05/18/2026. The filing date is within the usual Section 16 reporting window for these transactions (no late filing indicated).
Context
- These entries involve restricted stock units converting to shares (derivative transactions) and a new RSU grant — common forms of director compensation. The same‑day acquisition and disposition of the 26,873 shares is reported as a derivative exercise/conversion and subsequent disposition in the filing; the disposition is shown at $0.00 in the report. Warrants reported do not reflect an immediate cash purchase — they give the right to buy shares later at $15.50 each. As always, such compensation disclosures are factual reporting of awards and conversions and do not by themselves indicate the insider's view of the company's stock.
Insider Transaction Report
Form 4
Corbus Barclay
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-05-15+26,873→ 105,047 total - Award
Restricted Stock Units
[F2]2026-05-14+35,181→ 35,181 total→ Common Stock (35,181 underlying) - Exercise/Conversion
Restricted Stock Units
[F1]2026-05-15−26,873→ 0 total→ Common Stock (26,873 underlying) - Award
Common Stock Warrant
[F3]2025-10-07+7,816→ 7,816 totalExercise: $15.50From: 2025-12-03Exp: 2026-10-07→ Common Stock (7,816 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Bed Bath & Beyond, Inc. common stock. The restricted stock units vested at the close of business on May 15, 2026. Vested shares are delivered to the reporting person promptly after the restricted stock units vest. Amounts shown reflect restricted stock units from the subject grant beneficially owned following the transaction reported herein.
- [F2]Each restricted stock unit represents a contingent right to receive one share of Bed Bath & Beyond, Inc. common stock. The restricted stock units vest at the close of business on May 14, 2027. Vested shares are delivered to the reporting person promptly after the restricted stock units vest. Amounts shown reflect restricted stock units from the subject grant beneficially owned following the transaction reported herein.
- [F3]Represents warrants that were originally issued on October 7, 2025 as a pro-rata distribution to all holders of common stock. Each warrant entitles the holder to purchase one share of common stock at an exercise price of $15.50 per warrant. This distribution was exempt from immediate reporting under Section 16.
Signature
/s/ Christina Wheeler, Attorney-in-Fact|2026-05-18